These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 180871)

  • 21. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
    Kohara N
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium metabolism and kidney disease.
    Binswanger U
    Ergeb Inn Med Kinderheilkd; 1974; 34(0):105-53. PubMed ID: 4608434
    [No Abstract]   [Full Text] [Related]  

  • 23. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skeletal resistance to the calcaemic action of parathyroid hormone in uraemia: a mechanism for the hypocalcaemia and secondary hyperparathyroidism of chronic renal failure.
    Massry SG
    Clin Endocrinol (Oxf); 1976; 5 Suppl():317S-325S. PubMed ID: 1052781
    [No Abstract]   [Full Text] [Related]  

  • 25. Renal osteodystrophy in children: the role of vitamin D, phosphorus, and parathyroid hormone.
    Chesney RW; Mehls O; Anast CS; Brown E; Hammerman MR; Portale A; Fallon MD; Mahan J; Alfrey AC
    Am J Kidney Dis; 1986 Apr; 7(4):275-84. PubMed ID: 3515907
    [No Abstract]   [Full Text] [Related]  

  • 26. Calcium/phosphate imbalances, aluminum toxicity, and renal osteodystrophy.
    Brunier GM
    ANNA J; 1994 Jun; 21(4):171-7; quiz 178-9. PubMed ID: 8080326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin D: the discovery of its metabolites and their therapeutic applications.
    Beale MG; Chan JC; Oldham SB; Deluca HF
    Pediatrics; 1976 May; 57(5):729-41. PubMed ID: 181725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal osteodystrophy: role of calcimimetics.
    Hörl WH
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S104-7. PubMed ID: 12612964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium and phosphorus metabolism in the fanconi syndrome.
    Rodriguez Soriano J; Houston IB; Boichis H; Edelmann CM
    J Clin Endocrinol Metab; 1968 Nov; 28(11):1555-63. PubMed ID: 5697037
    [No Abstract]   [Full Text] [Related]  

  • 32. Renal secondary hyperparathyroidism in dogs.
    Stillion JR; Ritt MG
    Compend Contin Educ Vet; 2009 Jun; 31(6):E8. PubMed ID: 19746344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Secondary hyperparathyroidism in chronic kidney failure].
    Kalinin AP; Ivanov IA; Shcherbakova EO
    Ter Arkh; 1986; 58(8):143-8. PubMed ID: 3532407
    [No Abstract]   [Full Text] [Related]  

  • 34. Renal bone disease in peritoneal dialysis.
    Cunningham J
    Perit Dial Int; 1999; 19 Suppl 2():S397-401. PubMed ID: 10406553
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
    Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
    Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some biochemical, histological, radiological and clinical features of renal osteodystrophy.
    Eastwood JB; Bordier PJ; de Wardener HE
    Kidney Int; 1973 Aug; 4(2):128-40. PubMed ID: 4583084
    [No Abstract]   [Full Text] [Related]  

  • 39. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vitamin D metabolism and chronic kidney insufficiency].
    Schaefer K; von Herrath D; Kraft D
    Dtsch Med Wochenschr; 1973 Jul; 98(27):1338-44. PubMed ID: 4351844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.